Aehr Test Systems
AEHR
$84.64
-2.95%
Aehr Test Systems designs, manufactures, and markets advanced test and burn-in equipment for the semiconductor industry, with its FOX-P and ABTS product families used to stress-test logic, memory, optical, and power devices across the manufacturing flow. The company is a niche, highly specialized player rather than a broad-line equipment vendor, deriving its competitive identity from wafer-level and package-level burn-in systems that customers use to screen for early-life failures in mission-critical chips. The current investor narrative has been transformed by Aehr's pivot away from its historical automotive and EV customer concentration toward AI data-center infrastructure, where surging demand for power semiconductors and high-reliability processors has driven record bookings and a string of outsized order announcements. Management's disclosure of roughly $37.2 million in new bookings and expectations that revenue could triple in the coming fiscal year have made this a high-beta AI-adjacent growth story, even as the company's tiny 138-person workforce and lumpy, concentrated customer base keep execution risk front and center.…
AEHR
Aehr Test Systems
$84.64
Related headlines
Investment Opinion: Should I buy AEHR Today?
We assign a Hold rating on AEHR, balancing the explosive AI-driven growth potential against an extreme valuation and fragile profitability. The analyst consensus average target of $128.00 implies 51% upside, but the lack of a formal consensus recommendation and predominantly Hold ratings suggest limited conviction. The core thesis is that Aehr's technology is critical for testing AI power semiconductors, but the current price already discounts a near-flawless execution of the revenue ramp.
The supporting evidence includes a 40.19% year-over-year revenue growth in Q4, a 10.33 current ratio with minimal debt, and a 40.6% gross margin that is recovering. However, the trailing PS of 56.6x and EV/Sales of 54.8x are 4-10x the industry norm, and the company still has negative operating margins and free cash flow. The forward PE of 61.2x on estimated EPS of $1.65 requires a dramatic profitability swing that is not yet proven.
The biggest risks are customer concentration, the potential for order delays, and the stock's 3.48 beta which amplifies market swings. We would upgrade to Buy if revenue growth accelerates above 50% year-over-year with positive operating income, or if the PS ratio compresses below 30x. We would downgrade to Sell if bookings decline sequentially or if gross margins fall below 35%. Relative to its own history, the stock is in the upper-middle of its PS range (11x to 143x), but relative to peers it is significantly overvalued, leaving it fairly valued only under aggressive growth assumptions.
Sign up to view all
AEHR 12-Month Price Forecast
Aehr presents a high-risk, high-reward opportunity driven by its pivot to AI data-center testing. The revenue inflection and record bookings are promising, but the valuation is stretched and profitability is not yet sustainable. The stock's extreme volatility and recent technical weakness suggest that near-term upside may be limited without further positive catalysts. We would upgrade to bullish if the company demonstrates consistent revenue growth above $25 million per quarter with positive operating margins, and downgrade to bearish if bookings decline or gross margins fall below 35%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Aehr Test Systems's 12-month outlook, with a consensus price target around $128.00 and implied upside of +51.2% versus the current price.
Average Target
$128.00
0 analysts
Implied Upside
+51.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$110 - $175
Analyst target range
Five analysts cover Aehr, and the consensus average target price is $128.00, implying roughly 51% upside from the current price of $84.64. The target range spans $110.00 to $175.00, a spread of $65, or about 51% of the current price, which signals high uncertainty and low conviction in any single outcome. The recommendation field is listed as "none," meaning there is no clean consensus buy/hold/sell tally, but the institutional ratings history shows a predominantly cautious stance: Freedom Broker has reiterated Hold four times since October 2025, Craig-Hallum moved to Hold from Buy in March 2024, and only William Blair upgraded to Outperform from Market Perform in March 2026. The consensus therefore leans bullish on price targets but neutral-to-cautious on ratings, a classic divergence in a high-volatility small cap.
The high target of $175.00 assumes the AI-driven revenue ramp fully materializes, with revenue tripling and the company achieving the $1.65 consensus EPS, which would justify multiple expansion on a forward basis. The low target of $110.00 still implies 30% upside but prices in slower order conversion, margin compression from the current 40.6% gross margin, or customer concentration risk. The wide $65 spread, combined with the sparse five-analyst coverage and the absence of a formal consensus recommendation, indicates that price discovery is inefficient and that the stock is likely to remain volatile around earnings and booking announcements; the recent upgrade by William Blair is the only clearly positive rating action in the past year, while the repeated Holds suggest the sell-side is waiting for proof of durable, diversified demand before turning more constructive.
Bulls vs Bears: AEHR Investment Factors
The bull case rests on a powerful AI-driven revenue inflection, with Q4 revenue up 40.19% year-over-year and $37.2 million in record bookings that could triple revenue next year. The bear case centers on an extreme valuation of 56.6x trailing sales, fragile profitability with negative operating margins, and a technically damaged chart that has surrendered nearly half its peak gains. Currently, the bear evidence appears stronger on a risk-adjusted basis: the stock's 3.48 beta and 47.62% max drawdown mean that any disappointment could lead to severe losses, and the cautious analyst ratings suggest limited conviction in the growth story. The single most important tension is whether the AI-driven order pipeline converts into sustainable, diversified revenue at improving margins—if it does, the valuation could be justified; if it stalls, the multiple could compress dramatically.
Bullish
- Revenue inflecting sharply upward: Q4 FY2026 revenue of $19.75 million grew 40.19% year-over-year and nearly doubled sequentially from $10.31 million in Q3, confirming that the AI-driven order pipeline is converting into actual sales. This acceleration is the clearest evidence that Aehr's pivot from EV/automotive to AI data-center infrastructure is gaining traction.
- Record bookings signal future growth: Management disclosed roughly $37.2 million in new bookings, which is nearly double the most recent quarterly revenue and provides strong visibility into future periods. If these bookings convert on schedule, they support the consensus revenue estimate of $288.1 million, implying roughly 9.8x forward sales versus the current 56.6x trailing PS.
- Fortress balance sheet with zero debt: The current ratio is 10.33 and debt-to-equity is just 0.045, with $116.5 million in cash following a $79.9 million equity raise. This liquidity provides a multi-year runway to fund operations and R&D without dilutive financing, reducing near-term solvency risk despite negative free cash flow of -$5.38 million.
- Analyst targets imply substantial upside: The five-analyst average target price is $128.00, representing 51% upside from the current $84.64, with a high target of $175.00. Even the lowest target of $110.00 implies 30% upside, suggesting that sell-side models are pricing in successful execution of the AI growth narrative.
Bearish
- Extreme valuation leaves no margin for error: The stock trades at a trailing PS of 56.6x and EV/Sales of 54.8x, which is 4-10x the typical 5-15x range for mature semiconductor equipment makers. This premium prices in near-flawless execution of the revenue ramp, and any shortfall in bookings or revenue recognition could trigger a violent multiple compression given the 3.48 beta.
- Customer concentration and lumpy orders: Revenue is heavily dependent on a small number of large system orders, as evidenced by the sequential revenue swings from $9.88 million to $10.31 million to $19.75 million. With only 138 employees and a concentrated customer base, the loss or delay of a single major order could significantly impact quarterly results.
- Profitability remains fragile: Despite positive net income of $1.39 million in Q4, operating income was -$0.99 million and the trailing operating margin is -28.3%. The net income was aided by a $1.85 million income tax benefit, and trailing free cash flow is -$5.38 million, indicating the company is not yet self-funding its growth.
- Severe technical deterioration: The stock is down 11.43% over the past month versus a 2.12% gain for SPY, with a relative strength of -13.55%, and it fell 21% in just five trading days from October 2 to October 9. The 47.62% maximum drawdown and 51% position within the 52-week range highlight the risk of further mean reversion.
AEHR Technical Analysis
Aehr is in a powerful but extraordinarily volatile uptrend, with the shares up 236.5% over the trailing year and 281.9% year-to-date, massively outperforming the S&P 500's 16.0% and 14.2% respective gains. At $84.64, the stock sits at roughly 51% of its 52-week range (low of $18.70, high of $147.40), meaning it has surrendered nearly half of its peak gains despite the enormous annual advance. That positioning is neither a clean breakout nor a washed-out value setup: it reflects a stock that ran to an extreme, then entered a violent corrective phase, leaving it in the middle of its range where direction is genuinely contested. The 47.62% maximum drawdown confirms that this is a name where momentum can reverse violently, and the 51% range position argues against chasing strength without confirmation.
Short-term momentum has deteriorated sharply and is diverging bearishly from the longer-term trend. The stock is down 11.43% over the past month versus a 2.12% gain for SPY, producing a relative strength reading of -13.55%, even though the 3-month change remains positive at 16.58% and the 6-month at 20.18%. This pattern, strong 1-year and 3-month performance but negative 1-month, is characteristic of a parabolic move that has entered a mean-reversion phase rather than a confirmed trend reversal. The most recent sessions reinforce the weakness: the stock fell from $107.21 on October 2 to $84.64 by October 9, a roughly 21% slide in five trading days, on volume of about 2.07 million shares, suggesting distribution rather than orderly profit-taking.
Key technical levels are well defined by the 52-week extremes: support sits near the $18.70 low, though a more relevant near-term floor is the $65.40 close from late July, while resistance is anchored at the $147.40 high with intermediate supply around $117-$129 where the August rally stalled. A decisive break above $147.40 would signal a fresh leg of the AI-driven re-rating, whereas a breakdown below the $65-$70 zone would confirm that the July correction was the start of a deeper downtrend. With a beta of 3.484, Aehr is roughly 3.5 times as volatile as the broader market, meaning position sizing must be dramatically smaller than for a typical equity; a 1% market move can translate into a 3.5% swing here, and the 47.62% max drawdown is a direct consequence of that leverage to sentiment.
Beta
3.48
3.48x market volatility
Max Drawdown
-47.6%
Largest decline past year
52-Week Range
$19-$147
Price range past year
Annual Return
+236.5%
Cumulative gain past year
| Period | AEHR Return | S&P 500 |
|---|---|---|
| 1m | -11.4% | +1.9% |
| 3m | +16.6% | +3.9% |
| 6m | +20.2% | +12.1% |
| 1y | +236.5% | +19.2% |
| ytd | +281.9% | +14.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
AEHR Fundamental Analysis
Aehr's revenue trajectory has inflected sharply upward after a prolonged trough. The most recent quarter (period ending May 29, 2026) delivered revenue of $19.75 million, up 40.19% year-over-year, a dramatic acceleration from the $10.31 million reported in the February quarter and the $9.88 million in the November quarter. The sequential progression from $9.88 million to $10.31 million to $19.75 million shows a business that was essentially flat for two quarters before nearly doubling, consistent with the record bookings narrative and the AI-driven order flow. Within the segment mix, Systems generated $6.76 million, Contactors $2.61 million, and Services $1.59 million, confirming that hardware system sales remain the primary growth engine and that the revenue base is still heavily dependent on a small number of large system orders.
Profitability is thin and inconsistent, though the latest quarter crossed into positive territory. Net income was $1.39 million in the May quarter, a 7.04% net margin, a sharp reversal from losses of $3.20 million and $3.23 million in the two preceding quarters. Gross margin was 40.6% in the latest quarter, up from 32.7% and 25.7% in the prior two periods, but still well below the 53.95% gross margin posted in the August 2024 quarter, indicating that the current revenue mix is less favorable or that pricing has compressed. Operating income remained negative at -$0.99 million, and the trailing operating margin is -28.3%, so the company is not yet sustainably profitable on an operating basis despite the headline net income figure, which was aided by a $1.85 million income tax benefit.
The balance sheet is exceptionally strong and provides a substantial cushion. The current ratio stands at 10.33, debt-to-equity is just 0.045, and cash at the end of the May quarter was $116.5 million, up from $37.1 million, reflecting a $79.9 million common stock issuance that materially strengthened liquidity. However, free cash flow remains negative on a trailing basis at -$5.38 million, and the latest quarter's FCF of $1.08 million was barely positive, meaning the company is not yet self-funding its growth. ROE is -3.25% and ROA is -4.47%, both negative, and with a cash conversion cycle of 345 days and inventory days of 317, working capital is a significant drag; the company depends on its equity capital raises rather than internal cash generation to fund operations.
Quarterly Revenue
$19751000.0B
2026-05
Revenue YoY Growth
+40.2%
YoY Comparison
Gross Margin
40.6%
Latest Quarter
Free Cash Flow
$-5376000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is AEHR Overvalued?
Because Aehr's trailing net income is negative (EPS of -$0.0025, trailing PE of -401.4), the PE ratio is not meaningful, and the appropriate primary metric is the price-to-sales ratio. The stock trades at a trailing PS of 56.6x and an EV/Sales of 54.8x, extraordinarily rich multiples that reflect the market's expectation of explosive revenue growth rather than current fundamentals. The forward PE of 61.2x, based on estimated EPS of $1.65, implies the market expects the company to swing to meaningful profitability, and the enormous gap between the negative trailing PE and the positive forward PE captures the entire bull case: a transition from breakeven to roughly $1.65 in earnings per share within a year.
Relative to the semiconductor industry, where mature equipment makers typically trade at 5-15x sales and 20-30x earnings, Aehr's 56.6x PS and 54.8x EV/Sales represent a massive premium, on the order of 4-10x the sector norm. This premium is only defensible if the projected revenue ramp materializes: consensus estimates call for average revenue of $288.1 million, which against a current market cap of $2.83 billion implies roughly 9.8x forward sales, still expensive but far more reasonable than the trailing figure. The premium is therefore a bet on execution of the AI-driven order pipeline, not on current profitability, and any shortfall in bookings or revenue recognition would compress the multiple violently given the 3.48 beta.
Historically, Aehr's PS ratio has ranged from roughly 11x (May 2022) to 143x (May 2026), with the current 56.6x sitting in the upper-middle portion of that band but well below the 143x peak recorded just one quarter ago. The PB ratio of 12.9x is near the high end of its historical range, which has spanned roughly 2.3x to 18.2x, reflecting both the equity raise and the elevated share price. The compression from 143x PS to 56.6x PS occurred alongside a rising stock price, meaning revenue growth is beginning to catch up to valuation, a constructive sign, but the current level still prices in near-flawless execution and leaves little margin for error.
PE
-401.4x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 4x~168x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-332.1x
Enterprise Value Multiple
Investment Risk Disclosure
Aehr's financial risks are substantial despite a strong balance sheet. The company has a trailing operating margin of -28.3% and negative free cash flow of -$5.38 million, meaning it is not yet self-funding. Revenue is highly concentrated in a few large system orders, as shown by the sequential revenue swings from $9.88 million to $10.31 million to $19.75 million, and a cash conversion cycle of 345 days with inventory days of 317 ties up working capital. The $116.5 million cash cushion from the equity raise provides a runway, but continued losses could force further dilution.
Market and competitive risks are amplified by the stock's extreme volatility and premium valuation. With a beta of 3.484, Aehr is roughly 3.5 times as volatile as the broader market, and its 56.6x trailing PS ratio is 4-10x the sector norm, leaving it vulnerable to any slowdown in AI infrastructure spending or a rotation away from high-multiple small caps. The recent 21% five-day slide from $107.21 to $84.64 on elevated volume suggests distribution, and the relative strength of -13.55% over the past month indicates underperformance versus SPY. Competitive threats from larger, better-capitalized test equipment vendors could also pressure pricing and market share.
The worst-case scenario would involve a delay or cancellation of major AI-related orders, causing revenue to miss the $288.1 million consensus estimate and triggering a sharp multiple compression. Given the 52-week low of $18.70 and the analyst low target of $110.00, a realistic downside could see the stock retest the $65-$70 support zone, representing a decline of roughly 17-23% from the current $84.64. In a more severe scenario where the AI narrative breaks, the stock could fall toward the 52-week low of $18.70, a loss of approximately 78% from current levels, though the analyst low target of $110.00 suggests that even the bear case on the sell-side implies upside.
FAQ
The most severe risk is customer concentration, as revenue depends on a small number of large system orders, evidenced by the sequential revenue swings from $9.88 million to $19.75 million. Financial risk is also high, with negative operating margins of -28.3% and negative free cash flow of -$5.38 million, meaning the company relies on its cash reserves. Market risk is amplified by the 3.484 beta, which can lead to sharp declines in a sell-off, as seen in the 47.62% max drawdown. Competitive risk exists from larger test equipment vendors that could pressure pricing and market share. Finally, valuation risk is significant, as the 56.6x PS ratio could compress rapidly if growth disappoints.
Our 12-month forecast has a base case (50% probability) with a target range of $110-$128, assuming revenue meets the $288.1 million consensus and gross margins stabilize around 40-45%. The bull case (30% probability) targets $147-$175, driven by successful conversion of the $37.2 million bookings and new customer wins. The bear case (20% probability) targets $65-$110, reflecting order delays or a broader tech sell-off. The most likely scenario is the base case, which implies a return of 30-51% from the current $84.64, but this is contingent on execution. The key assumption is that AI infrastructure spending remains robust and Aehr converts its pipeline into revenue.
AEHR appears significantly overvalued on trailing metrics, with a PS ratio of 56.6x and EV/Sales of 54.8x, compared to the semiconductor equipment industry average of 5-15x. However, on a forward basis, the consensus revenue estimate of $288.1 million implies a forward PS of approximately 9.8x, which is still above the industry norm but more reasonable. The forward PE of 61.2x on estimated EPS of $1.65 also suggests a premium valuation. The market is pricing in explosive growth and a swing to profitability, leaving little room for error. Relative to its own history, the PS ratio has ranged from 11x to 143x, so the current level is in the upper-middle, but the stock is clearly overvalued relative to peers unless the growth materializes.
AEHR is a high-risk, high-reward investment that may be suitable only for investors with a high tolerance for volatility and a long-term horizon. The stock trades at a trailing PS of 56.6x, which is 4-10x the industry average, and has a beta of 3.484, meaning it is 3.5 times as volatile as the market. The analyst average target of $128.00 implies 51% upside, but the company still has negative operating margins and free cash flow, and its 47.62% max drawdown shows the potential for severe losses. A good entry point might be on a pullback to the $65-$70 support zone, but even then, position sizing should be small due to the extreme risk.
AEHR is more suitable for long-term investment by risk-tolerant investors, given its early-stage growth profile and the multi-year AI infrastructure build-out. The company pays no dividend and has a beta of 3.484, making it too volatile for short-term trading unless one is a skilled momentum trader. Earnings visibility is low due to lumpy orders, so a minimum holding period of 2-3 years is recommended to ride out volatility and allow the growth story to unfold. Short-term traders could exploit the wide swings, but the 47.62% max drawdown highlights the risk of timing errors. Overall, it fits a small, speculative allocation in a diversified portfolio.